Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you treat High risk inflammatory TNBC diagnosed in first trimester of pregnancy who underwent surgery? Is there a role for immunotherapy?
Related Questions
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
With the recent FDA approval of adjuvant ribociclib, how are you deciding on between adjuvant ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
Would you offer endocrine therapy to a patient with T1c tumor who was initially ER+ (15%)/PR negative/HER2-1+ but changed to a triple negative phenotype after neoadjuvant chemotherapy with TC?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
What are your top takeaways in Breast Cancer from ASTRO 2024?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
Would you send Oncotype for pre-menopausal women with HR+, HER2(-) breast cancer with a small tumor (pT1b) and micrometastatic LN involvement or recommend adjuvant chemotherapy without sending Oncotype?
